Medpace (NASDAQ:MEDP) Updates FY 2026 Earnings Guidance

Medpace (NASDAQ:MEDP) updated its FY 2026 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 16.680-17.500 for the period, compared to the consensus estimate of 15.830. The company issued revenue guidance of $2.8 billion-$2.9 billion, compared to the consensus revenue estimate of $2.7 billion.

Analysts Set New Price Targets

MEDP has been the topic of several recent research reports. Barclays upped their price objective on Medpace from $485.00 to $525.00 and gave the stock an “underweight” rating in a report on Monday, December 15th. Wall Street Zen upgraded shares of Medpace from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Robert W. Baird set a $613.00 price objective on Medpace in a research note on Friday, October 24th. Mizuho set a $660.00 price target on Medpace in a report on Friday, January 9th. Finally, TD Cowen reaffirmed a “sell” rating on shares of Medpace in a research note on Friday, October 24th. Two equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Reduce” and a consensus target price of $491.27.

Medpace Trading Down 2.2%

Shares of MEDP traded down $11.69 during trading hours on Monday, reaching $530.35. 790,679 shares of the company traded hands, compared to its average volume of 273,651. The stock’s fifty day moving average price is $578.30 and its 200 day moving average price is $539.57. The firm has a market cap of $14.94 billion, a price-to-earnings ratio of 37.09, a PEG ratio of 1.82 and a beta of 1.42. Medpace has a 12-month low of $250.05 and a 12-month high of $628.92.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, beating the consensus estimate of $4.18 by $0.49. The firm had revenue of $708.45 million during the quarter, compared to the consensus estimate of $689.53 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, research analysts forecast that Medpace will post 12.29 earnings per share for the current year.

Insider Activity

In other news, VP Susan E. Burwig sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $609.15, for a total value of $12,183,000.00. Following the completion of the sale, the vice president owned 27,500 shares of the company’s stock, valued at approximately $16,751,625. This represents a 42.11% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO August J. Troendle sold 59,025 shares of Medpace stock in a transaction on Monday, November 24th. The shares were sold at an average price of $607.78, for a total value of $35,874,214.50. Following the completion of the transaction, the chief executive officer owned 774,602 shares in the company, valued at $470,787,603.56. This represents a 7.08% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 320,192 shares of company stock worth $192,909,762. 20.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Medpace

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Geneos Wealth Management Inc. lifted its holdings in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the period. Quarry LP acquired a new stake in Medpace during the 3rd quarter valued at approximately $35,000. Johnson Financial Group Inc. increased its stake in shares of Medpace by 115.7% in the third quarter. Johnson Financial Group Inc. now owns 110 shares of the company’s stock worth $57,000 after acquiring an additional 59 shares during the period. Wilmington Savings Fund Society FSB raised its holdings in shares of Medpace by 124.1% during the third quarter. Wilmington Savings Fund Society FSB now owns 130 shares of the company’s stock worth $67,000 after purchasing an additional 72 shares during the last quarter. Finally, Employees Retirement System of Texas boosted its holdings in Medpace by 97.4% in the third quarter. Employees Retirement System of Texas now owns 229 shares of the company’s stock valued at $118,000 after purchasing an additional 113 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.